Avid Bioservices, Inc. provided revenue guidance for the fiscal 2023. For the revenue the company expects revenue of $140 million to $145 million, a 17-21% increase over fiscal 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.085 USD | +2.68% |
|
-10.99% | +9.00% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.00% | 450M | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023